Developing and maintaining a quality management system for IVDs

| October 12, 2018

article image
There are many different requirements with which in vitro diagnostic manufacturers must comply in order to place the product on the market. At the core of most of these requirements is a fundamental need to have a good quality management system (QMS) in place. This is certainly not a new requirement for companies. Philip B. Crosby said  ‘Quality Management is a systematic way of guaranteeing that organized activities happen the way that they are planned Quality management is needed because nothing is simple anymore if indeed it ever was’. Although this quote is now nearly 40 years old, it is as true today as it was then.

Spotlight

Bio-Pharm Inc.

Bio-Pharm, Inc. is a leading supplier of generic pharmaceutical formulations, where we constantly "build quality at every level." With deep dedication and a proactive approach to developing new products, Bio-Pharm invests heavily in R&D. Our state-of-the-art facilities compliment our talented scientists to deliver quality products on demand. Pharmaceutical manufacturing and research may start in a laboratory, but it ends with an individual - a living and breathing person. Our goal is to develop innovative and high-quality pharmaceuticals to improve millions of lives, one product at a time.

OTHER ARTICLES

3 Big Pharma Stocks Plunging the Most During the Coronavirus Stock Market Crash: Are They Buys?

Article | March 26, 2020

Big pharma stocks have been clobbered during the coronavirus-caused stock market crash. You can count the number of drugmakers with market caps of $25 billion or more whose shares haven't dropped by double-digit percentages on one hand -- and have several fingers left over. Three big pharma stocks have plunged the most: AbbVie (NYSE:ABBV), Bristol Myers Squibb (NYSE:BMY), and Pfizer (NYSE:PFE). But are these stocks smart picks to buy right now?

Read More

Roche Prepares to Launch COVID-19 Antibody Test System

Article | March 26, 2020

Swiss pharma giant Roche is joining the race to develop a test for COVID-19 antibodies in people who have been exposed to the disease. This morning, Roche announced the development and upcoming launch of its Elecsys Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the SARS-CoV-2, the virus that causes COVID-19. Roche is eying May for the launch of the test in Europe and is in talks with the U.S Food and Drug Administration for emergency approval of the system. Antibody testing is central to help identify people who have been infected by the virus, especially those who may have been infected but did not display symptoms, the company said. Roche noted that as more information becomes available about immunity levels to COVID-19, society can return to a sense of normal much more quickly. Roche’s test will join a number of other antibody tests that have recently come on the market. Earlier this month the U.S. Food and Drug Administration approved the first blood test for COVID-19 antibodies.

Read More

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | March 26, 2020

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Article | March 26, 2020

Pharmaceutical stocks have been somewhat of a safe haven for investors as the coronavirus outbreak spread from China to the rest of the world. But as the pandemic deepened, now resulting in more than 782,000 cases worldwide, even these "safer" companies are beginning to feel the effects. The U.S. is now the coronavirus epicenter, with the most cases -- more than 161,000 as of today. Initial concerns for drugmakers had to do with the supply of active pharmaceutical ingredients, which often come from China. The worry was that pharmaceutical companies wouldn't be able to produce enough of their drugs for patients.

Read More

Spotlight

Bio-Pharm Inc.

Bio-Pharm, Inc. is a leading supplier of generic pharmaceutical formulations, where we constantly "build quality at every level." With deep dedication and a proactive approach to developing new products, Bio-Pharm invests heavily in R&D. Our state-of-the-art facilities compliment our talented scientists to deliver quality products on demand. Pharmaceutical manufacturing and research may start in a laboratory, but it ends with an individual - a living and breathing person. Our goal is to develop innovative and high-quality pharmaceuticals to improve millions of lives, one product at a time.

Events